Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)

Next Previous
Trial Profile

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Bicalutamide; Gonadotropin releasing hormone; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms FORMULA-509

    • Most Recent Events

    • 27 Jan 2024 Results of Patient-reported health-related quality of life , presented at the 2024 Genitourinary Cancers Symposium
    • 18 Feb 2023 Primary endpoint (PSA Progression Free Survival) has not been met, as per results presented at the 2023 Genitourinary Cancers Symposium.
    • 18 Feb 2023 Results assessing the efficacy and safety of abiraterone acetate/prednisone (AAP) and apalutamide (Apa) in patients with post-radical prostatectomy, presented at the 2023 Genitourinary Cancers Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top